Characterization of the Essure System Tubal Sterilization Using Ultrasound and X-Ray

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT00588497
Collaborator
(none)
25
1
24.9
1

Study Details

Study Description

Brief Summary

Tubal sterilization is the most prevalent form of contraception in the United States and the world. Currently, approximately half of these are performed with a laparoscope and half through a mini-laparotomy after delivery. Micro-insert hysteroscopic sterilization system received FDA approval for elective sterilization in 2003. Compared to other forms of female sterilization, this procedure is minimally invasive and does not require entering the abdominal cavity. In addition, it is at least as effective in preventing pregnancy as other forms of tubal occlusion. Given the distinct advantages of this method, it could become the preferred method of tubal sterilization for physicians and their patients. Currently, there is no published data concerning the appearance of the micro-inserts system using other imaging modalities that are commonly used in gynecologic practice. As the use of this device becomes more widespread it will be more commonly encountered in radiographic imaging performed as part of routine patient care. The main objective of this study is to provide important descriptive data concerning the ultrasonographic and x-ray appearance of the micro-insert hysteroscopic sterilization device. An additional objective of this study is to identify characteristics on plain film and ultrasound (US) that correlate with tubal occlusion or patency.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Micro-insert hysteroscopic sterilization
  • Radiation: Plain abdominal Xray
  • Procedure: Pelvic Ultrasound
  • Radiation: Hysterosalpingogram

Study Design

Study Type:
Observational
Actual Enrollment :
25 participants
Time Perspective:
Prospective
Official Title:
Characterization of the Essure System Tubal Sterilization Using Ultrasound and X-Ray
Study Start Date :
Feb 1, 2004
Actual Primary Completion Date :
Mar 1, 2006
Actual Study Completion Date :
Mar 1, 2006

Arms and Interventions

Arm Intervention/Treatment
Study Group

Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.

Procedure: Micro-insert hysteroscopic sterilization
Placement of micro-inserts transcervically with the aid of a hysteroscope

Radiation: Plain abdominal Xray
Performed immediately after micro-inserts placement and at 3 months

Procedure: Pelvic Ultrasound
Performed immediately after micro-inserts placement and at 3 months.

Radiation: Hysterosalpingogram
Performed 3 months after micro-inserts placement

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients requesting sterilization
    Exclusion Criteria:
    • Unsuccessful placement of the hysteroscopic sterilization system in one or both fallopian tubes. In addition, a patient will not be offered the opportunity to participate in the study if there are any conditions that would preclude attempted placement of the hysteroscopic sterilization system. These include hypersensitivity to nickel-titanium or contrast media, current or recent pregnancy (within the previous six weeks), active genital tract infection, prior tubal ligation, or known congenital uterine malformation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic Rochester Minnesota United States 55902

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Abimbola O. Famuyide, M.D., Mayo Clinic, Rochester, MN

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00588497
    Other Study ID Numbers:
    • 628-04
    First Posted:
    Jan 8, 2008
    Last Update Posted:
    May 23, 2011
    Last Verified:
    May 1, 2011

    Study Results

    No Results Posted as of May 23, 2011